MedTrace Logo

Factors Associated to Success of Hepatitis C Therapy

NCT00514111 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-03-20

No results posted yet for this study

Summary

The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.

Conditions

  • Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

Interventions

DRUG

pegylated-interferon, conventional-interferon, ribavirin

Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.

Sponsors & Collaborators

  • UPECLIN HC FM Botucatu Unesp

    lead OTHER

Principal Investigators

  • Alexandre N Barbosa, MD, MSc · UPECLIN HC FM Botucatu Unesp

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-07-31
Completion
2008-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514111 on ClinicalTrials.gov